急性髓性细胞白血病的分子遗传学研究进展

王龙; 徐燕丽

急性髓性细胞白血病的分子遗传学研究进展

王龙,
徐燕丽^,

- 南京医科大学附属南京医院(南京市第一医院)血液科(南京, 210006)

详细信息

通讯作者: 徐燕丽,E-mail:xuyanli62@sohu.com

中图分类号: R733.71

收稿日期: 2012-06-16

Advances in molecular genetics of acute myeloid leukemia

WANG Long,
XU Yanli^,

More Information

Corresponding author: XU Yanli, E-mail: xuyanli62@sohu.com

Received Date: 16 June 2012

摘要

- 急性髓性细胞白血病 /
- 正常核型 /
- 预后 /
- 分子遗传学
Abstract: Genomics technology is widely applied in acute myeloid leukemia (AML) at present.A large number of abnormal genes associated with AML have been found in succession.However,there are 40% to 49% patients who were the normal karyotype (NK) in AML.For this reason,it is very important to supplement the molecular genetics studies to assess the prognosis of NK-AML patients.Therefore,new genes have the great significance in improving the prognosis of AML classification and guiding the diagnosis and treatment of NK-AML patients.
- acute myeloid leukemia /
- normal karyotype /
- prognosis /
- molecular genetics

HTML全文

参考文献(20)

[1]	MROZEK K,MARCUCCI G,PASCHKA P,et al.Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics:are we ready for a prognostically prioritized molecular classification?[J].Blood,2007,109:431-448.
[2]	MCDEVITT M A.Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies[J].Semin Oncol,2012,39:109-122.
[3]	HOU H A,KUO Y Y,LIU C Y,et al.DNMT3A mutations in acute myeloid leukemia:stability during disease evolution and clinical implications[J].Blood,2012,119:559-568.
[4]	LEY T J,DING L,WALTER M J,et al.DNMT3A mutations in acute myeloid leukemia[J].N Engl J Med,2010,363:2424-2433.
[5]	LAROCHELLE O,BERTOLI S,VERGEZ F,et al.Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin?[J].Oncotarget,2011,2:850-861.
[6]	PATEL J P,GONEN M,FIGUEROA M E,et al.Prognostic relevance of integrated genetic profiling in acute myeloid leukemia[J].N Engl J Med,2012,366:1079-1089.
[7]	米瑞华,吕晓东,魏旭东,等.急性髓系白血病患者IDH1和IDH2基因突变的检测及其临床意义[J].中华血液学杂志,2011,32(9):610-613.
[8]	SCHNITTGER S,HAFERLACH C,ULKE M,et al.IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status[J].Blood,2010,116:5486-5496.
[9]	THOL F,DAMM F,WAGNER K,et al.Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia[J].Blood,2010,116:614-616.
[10]	PASCHKA P,SCHLENK R F,GAIDZIK V I,et al.IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication[J].J Clin Oncol,2010,28:3636-3643.
[11]	ROCKOVA V,ABBAS S,WOUTERS B J,et al.Risk stratification of intermediate-risk acute myeloid leukemia:integrative analysis of a multitude of gene mutation and gene expression markers[J].Blood,2011,118:1069-1076.
[12]	BERMAN J N,GERBING R B,ALONZO T A,et al.Prevalence and clinical implications of NRAS mutations in childhood AML:a report from the Children's Oncology Group[J].Leukemia,2011,25:1039-1042.
[13]	PARK S H,CHI H S,MIN S K,et al.Prognostic impact of C-kit mutations in core binding factor acute myeloid leukemia[J].Leuk Res,2011,35:1376-1383.
[14]	张寒,郑胡镛.RUNX1表观遗传机制在白血病发生中的作用研究进展[J].中国实验血液学杂志,2010,18(2):525-530.
[15]	SILVA F P,SWAGEMAKERS S M,ERPELINCK-VERSCHUEREN C,et al.Gene expression profiling of minimally differentiated acute myeloid leukemia:M0 is a distinct entity subdivided by RUNX1 mutation status[J].Blood,2009,114:3001-3007.
[16]	TANG J L,HOU H A,CHEN C Y,et al.AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia:prognostic implication and interaction with other gene alterations[J].Blood,2009,114:5352-5361.
[17]	CARBUCCIA N,TROUPLIN V,GELSI-BOYER V,et al.Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias[J].Leukemia,2010,24:469-473.
[18]	CHOU W C,HUANG H H,HOU H A,et al.Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1(ASXL1) mutations[J].Blood,2010,116:4086-4094.
[19]	BAKER L A,ALLIS C D,WANG G G.PHD fingers in human diseases:disorders arising from misinterpreting epigenetic marks[J].Mutat Res,2008,647(1-2):3-12.
[20]	VAN VLIERBERGHE P,PATEL J,ABDEL-WAHAB O,et al.PHF6 mutations in adult acute myeloid leukemia[J].Leukemia,2011,25:130-134.